17 completed, 5 terminated, 3 withdrawn, 1 unknown. 18 Phase 1, 11 Phase 2, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Completed 13, Terminated 3, Unknown 1, Withdrawn 1 |
| Phase 2 | 11 | Completed 8, Terminated 3 |
| Phase 3 | 5 | Completed 2, Withdrawn 2, Terminated 1 |
Follow CureVac: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC) CV09070101 mRNA vaccine (CVHNLC) 50 µg, CV09070101 mRNA vaccine (CVHNLC) 100 µg, CV09070101 mRNA vaccine (CVHNLC) 200 µg - Squamous NSCLC | Phase 1 | Withdrawn | CureVac | 2025-07-30 | 2026-05-29 | |
| A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults CV0701 mRNA COVID-19 Vaccine (Low dose), CV0701 mRNA COVID-19 Vaccine (Medium dose), CV0701 mRNA COVID-19 Vaccine (High dose) - SARS-CoV-2, COVID-19 | Phase 2 | Completed | GlaxoSmithKline | 692 | 2023-08-01 | 2025-10-23 |
| Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma CV09050101 mRNA vaccine (CVGBM) 12 μg, CV09050101 mRNA vaccine (CVGBM) 25 μg, CV09050101 mRNA vaccine (CVGBM) 50 μg - Glioblastoma | Phase 1 | Completed | CureVac | 37 | 2023-06-01 | 2026-02-18 |
| A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults F2C22C/DL001Z, F2B22A/DL001Z, F2B22B/DL001Z - Influenza, Human | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 1275 | 2023-04-27 | 2025-07-23 |
| A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults GSK4382276A Dose level 1, GSK4382276A Dose level 2, GSK4382276A Dose level 3 - Influenza, Human | Phase 1 | Completed | GlaxoSmithKline | 324 | 2022-08-09 | 2026-03-10 |
| Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants CV2CoV (2 µg), CV2CoV (4 µg), CV2CoV (8 µg) - COVID-19, SARS-CoV-2 | Phase 1 | Completed | GlaxoSmithKline | 99 | 2022-03-24 | 2024-08-12 |
| A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults CVSQIV - Influenza | Phase 1 | Completed | CureVac | 240 | 2022-02-07 | 2023-06-06 |
| COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older SARS-CoV-2 mRNA Vaccine (CVnCoV), Quadrivalent influenza vaccine (QIV), Placebo - SARS-CoV-2 Infection, Coronavirus Disease 2019 (COVID-19) | Phase 3 | Withdrawn | Bayer | 2021-10-01 | 2021-08-11 | |
| A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19 CVnCoV Vaccine - Coronavirus, Covid19 | Phase 3 | Withdrawn | CureVac | 2021-10-01 | 2021-08-20 | |
| COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities CVnCoV Vaccine - Coronavirus, Covid19 | Phase 3 | Terminated | CureVac | 129 | 2021-04-22 | 2022-05-13 |
| A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19 CVnCoV Vaccine, Placebo - Coronavirus, Covid19 | Phase 3 | Completed | CureVac | 2357 | 2020-12-23 | 2023-10-06 |
| A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older CVnCoV, Placebo, Authorized/licensed vaccines for preventing COVID-19 (AV) as standard of care through their national vaccination program - Covid19, SARS-CoV-2 | Phase 2 / Phase 3 | Completed | CureVac | 39680 | 2020-12-11 | 2024-04-29 |
| A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 CVnCoV 6 μg, CVnCoV 12 μg, Hepatitis A vaccine - Coronavirus, Covid19 | Phase 2 | Completed | CureVac | 668 | 2020-09-21 | 2023-09-28 |
| A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 CVnCoV Vaccine, Placebo - Severe Acute Respiratory Syndrome, Coronavirus | Phase 1 | Completed | CureVac | 280 | 2020-06-18 | 2023-01-30 |
| A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults Rabipur®, Rabies mRNA vaccine CV7202 - Rabies | Phase 1 | Completed | CureVac | 53 | 2018-10-12 | 2024-12-19 |
| Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC Durvalumab, Tremelimumab, BI 1361849 - Metastatic Non-small Cell Lung Cancer, NSCLC | Phase 1 / Phase 2 | Completed | Ludwig Institute for Cancer Research | 61 | 2017-12-20 | 2022-10-10 |
| Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC CV8102, CV8102 + anti-PD-1 therapy - Melanoma (Skin), Squamous Cell Carcinoma of the Skin | Phase 1 | Unknown | CureVac | 98 | 2017-09-25 | 2021-11-04 |
| IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients IMA970A plus CV8102 and Cyclophosphamide - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute, Naples | 22 | 2017-09-18 | 2020-02-05 |
| Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults CV8102, Rabipur, CV8102 + Rabipur - Rabies | Phase 1 | Completed | CureVac | 72 | 2014-09-01 | 2018-06-06 |
| An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer CV9104, needle free injection device (Tropis®) - Prostate Carcinoma | Phase 2 | Terminated | CureVac | 35 | 2014-06-01 | 2016-06-13 |
Showing 20 of 26. Sign in to see all of them.
COVID-19 (9) · Coronavirus Infections (5) · Severe Acute Respiratory Syndrome (5) · Carcinoma, Non-Small-Cell Lung (3) · Influenza, Human (3) · Rabies (3) · Prostatic Neoplasms (2) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Hepatocellular (1) · Glioblastoma (1) · Melanoma (1) · Neoplasm Metastasis (1) · Squamous Cell Carcinoma of Head and Neck (1)
CVnCoV COVID-19 vaccine (7) · Cyclophosphamide (1) · Hepatitis A Vaccines (1) · Influenza Vaccines (1) · Pneumococcal Vaccines (1) · durvalumab (1) · tremelimumab (1)
Germany (14) · Belgium (8) · Spain (6) · United States (6) · France (3) · Panama (3) · Switzerland (3) · Austria (2) · Canada (2) · Italy (2) · Netherlands (2) · Peru (2) · United Kingdom (2) · Argentina (1) · Australia (1)
Alexander Knuth, Prof. Dr. (1) · Alfred Zippelius, Prof. Dr. (1) · Arnulf Stenzl, Prof. Dr. (1) · Arnulf Stenzl, Prof. Dr. med. (1) · Franz-Josef Falkner von Sonnenburg, MD (1) · Ingo Meyer, MD (1) · Jhanelle Gray, MD (1) · Johannes Vieweg, MD FACS (1) · Kurt Miller, Professor (1) · Thomas Eigentler, Prof. Dr. (1)
PMID 21150709, PMID 25288198, PMID 28754494, PMID 30736848, PMID 33487468, PMID 34826381, PMID 35421231, PMID 36319717, PMID 39040887, PMID 39904560, PMID 41051649, PMID 41701031, PMID 42647564, PMID 42875683
2017 (1)